Stern Investor Relations

What Stern Investor Relations does

Stern Investor Relations is a New York-based investor relations firm founded in 1998 that specializes in financial communications and strategic counsel for entrepreneurial biotechnology and healthcare companies. Founded by Lilian Stern, the firm appears to have been integrated into Precision AQ's broader healthcare commercialization platform, where it now operates as a dedicated Investor Relations & External Communications service line alongside public relations capabilities. The founding entity remains small in headcount (11–50 employees), while operating within a much larger parent platform.

The combined Precision AQ platform delivers a stack of integrated capabilities: Value & Access consulting (HEOR evidence generation, payer strategy, payer marketing), Medical Communications (peer-to-peer marketing, medical affairs, learning & development), Brand Strategy & Marketing, and Data/Insights/Analytics across patient, payer, and provider dimensions. Underpinning the services are five proprietary product offerings — AccessGenius (market access evaluation), OncoGenius (oncology-specific analytics), Data Solutions, EHR Solutions, and Omnichannel Solutions — that extend the firm beyond pure consulting into recurring data/subscription revenue.

Revenue is generated primarily through professional-services engagements (consulting, HEOR, IR, medical communications, brand strategy) with a growing mix of product-subscription revenue. Customer segments are large and mid-size pharmaceutical companies and biotechnology firms, including those in rare disease and specialty areas. The firm claims 50% of all FDA-approved drugs in 2024 were launched with its involvement and operates across US and UK sites.

Name

Stern Investor Relations

Legal name

Precision AQ

Website

https://sternir.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Stern Investor Relations is a New York-based IR firm founded in 1998 that provides financial communications and strategic counsel to entrepreneurial biotechnology and healthcare companies, operating within Precision AQ's broader healthcare commercialization platform.

Ownership category

akta.pro rank

Product category

Investor Relations and External Communications Services

NAICS

Public Relations Agencies (541820), Investment Banking and Securities Intermediation (523150)

SIC

Investment Advice (6282)

akta.pro primary industry

Investor Relations (IR) & Capital Markets Communications (MPAAADAH)

akta.pro secondary industry

Corporate & Financial Communications PR (MPAAADAA)

Keywords

• Investor relations services
• Biotech IR consulting
• Healthcare investor communications
• Financial communications advisory
• Investor outreach services

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Professional Services - Access Consulting & HEOR: Consulting engagements providing health economics outcomes research (HEOR) evidence, payer strategy, and payer marketing services to help navigate payer complexities and optimize commercial success
2. Medical Communications: Peer-to-peer marketing, medical affairs, and learning & development services for pharma and biotech clients
3. Investor Relations & External Communications: Services facilitating engagement with financial community and helping clients reach financial goals
4. Brand Strategy & Marketing: Market strategies, brand identity development, and market presence enhancement with payers, providers, and patients
5. Product Solutions: Proprietary products including AccessGenius, OncoGenius, Data Solutions, EHR Solutions, and Omnichannel Solutions that power HCP, payer, and patient engagement

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Stern Investor Relations is an investor relations and external communications firm dedicated to entrepreneurial biotechnology and healthcare companies. The firm delivers IR and public relations services to help clients engage the financial community and reach their financial goals, supported by adjacent capabilities in market access, HEOR, medical communications, brand strategy, and proprietary technology platforms such as AccessGenius and OncoGenius.

Product overview

Precision AQ is a platform-plus-modules company offering a suite of integrated healthcare market access solutions. The core product portfolio consists of AccessGenius (access consulting), Data Solutions (market access data), EHR Solutions (electronic health record integration), Omnichannel Solutions (multi-channel engagement), and OncoGenius (oncology-specific analytics). These products work together to help pharma and biotech leaders transform patient access by integrating technology, data expertise, and strategic services across the commercialization journey.

Differentiator

Problem solved

Functional benefit

Brands

• AccessGenius: Product offering for market access solutions
• OncoGenius
• Data Solutions
• EHR Solutions
• Omnichannel Solutions

Products and services

• Investor Relations
• Public Relations
• Access Consulting
• HEOR (Health Economics and Outcomes Research)
• Medical Communications
• Brand Strategy & Marketing
• AccessGenius Proprietary product solution for market access evaluation and optimization that helps pharma and biotech leaders transform patient access through integrated technology, data expertise, and strategic services.
• OncoGenius Oncology-specific market potential evaluation and commercial impact solution for oncology-focused pharma and biotech clients.
• Data Solutions Proprietary data solutions for payer, provider, and patient insights used to support market access decisions and engagement strategies.
• EHR Solutions Proprietary electronic health record integration solutions enabling data connectivity for HCP, payer, and patient engagement.
• Omnichannel Solutions Proprietary multi-channel engagement solutions supporting HCP, payer, and patient outreach across the commercialization journey.

Quantifiable outcome

• 50% of all FDA-approved drugs in 2024 were launched with the company

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Lazar Partners: Lazar Partners is a healthcare-specialized strategic communications and IR firm serving biotech, pharma, and medical device clients. Comparable boutique positioning with parallel IR and external communications capabilities.
• ICR (ICR Inc.): ICR is one of the largest healthcare-specialized IR and strategic communications agencies, offering AOR-style engagements for biotech and pharma. Directly comparable to Stern IR in terms of IR-focused, healthcare-vertical agency model with adjacent PR and capital markets advisory services.
• Russo Partners: Russo Partners is a boutique healthcare and life-sciences IR and communications agency serving biotech and pharma. Comparable as a specialist boutique with overlapping service lines in IR, PR, and strategic communications.
• Westwicke Partners (an ICR company): Westwicke specializes in healthcare IR for public and pre-IPO biotech and medtech companies. Highly comparable on the IR-for-biotech axis, with similar target customer profile and AOR engagement model.
• Canale Communications: Canale Communications is a healthcare-focused PR and IR agency with deep biotech and life-sciences client base. Comparable target customers and overlapping IR/communications service offerings.

Broad incumbents

• Makovsky: Makovsky is a fully integrated communications agency with a strong health practice serving pharma and biotech. Comparable in healthcare PR and external communications but with a broader portfolio across multiple industries.
• Syneos Health (Communications arm): Syneos Health provides clinical and commercial services to pharma and biotech including a medical communications and patient engagement practice. Significantly larger incumbent with overlapping market access, medical communications, and commercial launch capabilities.
• PAN Communications: PAN Communications is a larger integrated marketing and communications agency with a dedicated healthcare and life sciences practice. Broader portfolio than Stern IR but overlapping in B2B healthcare PR and communications services.

Others

• Precision Medicine Group: Precision Medicine Group is the parent/affiliated organization referenced in the data via privacy policy domain. Operates adjacent services across commercial, medical, and patient solutions for biotech — enabling/complementary rather than directly competitive.

Emerging players

• Covenant Communications Group: Covenant Communications Group is a healthcare-focused communications firm serving biotech and pharma clients with PR and IR services. Comparable emerging specialist with overlapping customer base but smaller scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebooklinkedin.com/company/precision-aq
• LinkedInlinkedin.com/company/stern-investor-relations

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stern Investor Relations